S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Is There Still Time to Get In On the Lithium Boom? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Is There Still Time to Get In On the Lithium Boom? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Is There Still Time to Get In On the Lithium Boom? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
S&P 500   4,273.79
DOW   33,562.86
QQQ   354.90
Is Verizon’s 7% Yield Too Good To Pass Up?
Is There Still Time to Get In On the Lithium Boom? (Ad)
Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
The Most Upgraded Stocks In May Are Moving Higher 
Is There Still Time to Get In On the Lithium Boom? (Ad)
Dollar General May Create an Opportunity for Patient Investors
Buffett-Backed BYD Caught In The Chinese Government's Stimulus
Is There Still Time to Get In On the Lithium Boom? (Ad)
SunCar Technology Stock Overheats...Will it Rise Again?
How major US stock indexes fared Monday 6/5/2023
NASDAQ:ACXP

Acurx Pharmaceuticals (ACXP) Competitors

$2.91
-0.01 (-0.34%)
(As of 06/5/2023 ET)
Compare
Today's Range
$2.90
$2.97
50-Day Range
$2.76
$3.53
52-Week Range
$2.33
$4.85
Volume
7,647 shs
Average Volume
19,385 shs
Market Capitalization
$33.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

ACXP vs. NOVN, BFRG, PPBT, NERV, KALA, YMTX, CKPT, ORGS, LUMO, and EFTR

Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Novan (NOVN), Bullfrog AI (BFRG), Purple Biotech (PPBT), Minerva Neurosciences (NERV), Kala Pharmaceuticals (KALA), Yumanity Therapeutics (YMTX), Checkpoint Therapeutics (CKPT), Orgenesis (ORGS), Lumos Pharma (LUMO), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical preparations" industry.

Acurx Pharmaceuticals vs.

Novan (NASDAQ:NOVN) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, community ranking, earnings, profitability and analyst recommendations.

Novan has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -0.89, indicating that its stock price is 189% less volatile than the S&P 500.

Novan received 234 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Acurx Pharmaceuticals an outperform vote while only 61.92% of users gave Novan an outperform vote.

CompanyUnderperformOutperform
NovanOutperform Votes
239
61.92%
Underperform Votes
147
38.08%
Acurx PharmaceuticalsOutperform Votes
5
100.00%
Underperform Votes
No Votes

20.7% of Novan shares are owned by institutional investors. Comparatively, 13.1% of Acurx Pharmaceuticals shares are owned by institutional investors. 2.0% of Novan shares are owned by insiders. Comparatively, 30.9% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Novan. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Novan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novan$23.68 million1.36-$31.31 million-$1.32-0.87
Acurx PharmaceuticalsN/AN/A-$12.09 million-$1.11-2.62

Acurx Pharmaceuticals has a net margin of 0.00% compared to Novan's net margin of -128.61%. Acurx Pharmaceuticals' return on equity of -158.17% beat Novan's return on equity.

Company Net Margins Return on Equity Return on Assets
Novan -128.61% -700.28% -39.58%
Acurx Pharmaceuticals N/A -158.17% -133.39%

Novan presently has a consensus target price of $12.33, suggesting a potential upside of 972.46%. Acurx Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 381.10%. Given Novan's higher probable upside, equities research analysts plainly believe Novan is more favorable than Acurx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novan
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Acurx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Novan had 8 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 9 mentions for Novan and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.49 beat Novan's score of -0.05 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novan
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Acurx Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Novan and Acurx Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACXP vs. The Competition

MetricAcurx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$33.97M$5.48B$4.53B$6.26B
Dividend YieldN/A2.53%6.05%6.50%
P/E Ratio-2.629.15130.6914.41
Price / SalesN/A328.023,483.2088.34
Price / CashN/A20.5022.2723.57
Price / Book4.624.774.655.43
Net Income-$12.09M$145.54M$116.46M$192.41M
7 Day Performance0.34%3.81%2.19%2.14%
1 Month Performance-2.68%2.03%1.52%3.55%
1 Year Performance13.89%19.41%13.19%1.25%

Acurx Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NOVN
Novan
1.6605 of 5 stars
$1.19
+3.5%
$12.33
+936.4%
-56.4%$33.33M$23.68M-0.9029Analyst Revision
Positive News
Gap Down
BFRG
Bullfrog AI
0 of 5 stars
$5.45
+18.5%
N/AN/A$33.19MN/A0.00N/ANews Coverage
Positive News
Gap Up
PPBT
Purple Biotech
1.7284 of 5 stars
$1.79
-0.6%
$9.00
+402.8%
-41.4%$33.08M$1M-1.7019Gap Down
NERV
Minerva Neurosciences
1.5781 of 5 stars
$5.92
-0.8%
$8.00
+35.1%
+115.1%$32.97M$41.18M-1.089Analyst Report
KALA
Kala Pharmaceuticals
2.1232 of 5 stars
$14.55
-3.3%
$35.50
+144.0%
+66.9%$34.19M$3.89M-0.99192Positive News
YMTX
Yumanity Therapeutics
0 of 5 stars
$3.00
-1.3%
N/A+114.8%$32.57M$4.84M-1.0040Gap Down
CKPT
Checkpoint Therapeutics
1.9453 of 5 stars
$2.66
-1.1%
$18.67
+601.8%
-79.7%$34.45M$190,000.000.0014
ORGS
Orgenesis
1.9882 of 5 stars
$1.22
flat
$6.00
+391.8%
-52.0%$34.58M$36.03M-2.44111
LUMO
Lumos Pharma
2.0985 of 5 stars
$3.96
+5.0%
$17.67
+346.1%
-48.1%$32.35M$1.52M-1.0829High Trading Volume
EFTR
eFFECTOR Therapeutics
2.3069 of 5 stars
$0.82
+24.1%
$4.50
+446.6%
-43.6%$34.90M$3.55M-0.9612High Trading Volume

Related Companies and Tools

This page (NASDAQ:ACXP) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -